Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

Roche Partners with Dualitas Therapeutics to Develop Bispecific Drugs for Immune Diseases

Sep 17, 2026•about 2 hours ago

Contract Type

partnership

San FranciscoBiotechnologyresearch

Description

Roche has entered into a partnership with Dualitas Therapeutics, investing $36.5 million to explore new bispecific antibody combinations. Dualitas could earn up to $1 billion in future milestone payments and royalties, should they successfully advance new treatments for immune diseases.

Company Information

Company

Dualitas Therapeutics

Location

681 Gateway Boulevard Suite 411

San Francisco, California, United States

About

Dualitas Therapeutics is a biotechnology company pioneering the future of bispecific antibody therapies for immune and inflammatory (I&I) diseases and beyond. Powered by our proprietary DualScreen™ discovery engine and a growing library of novel cell surface proximity engagers, our pipeline—including lead programs DTX-103 and DTX-102—has demonstrated compelling preclinical evidence supporting its potential to address important unmet patient needs. We offer partnering opportunities on the next generation of bispecific therapies in I&I diseases – and beyond.

Related People

Marie
Likely contact at this company
••••••••@••••••••

See Marie's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Dualitas Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Dualitas Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.